NovaBridge Biosciences NBP
NovaBridge Biosciences (Nasdaq: NBP) is an oncology drug developer. Its lead program, Givastomig (TJ033721 / ABL111), Claudin 18.2 x 4-1BB bispecific antibody, is in Phase 2 for First-line HER2-negative metastatic gastric / gastroesophageal adenocarcinoma (GEA). Its next catalyst on record is VIS-101: Initiate Phase 2b program in nAMD (H2 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: VIS-101 — Initiate Phase 2b program in nAMD (H2 2026). 4 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Givastomig (global randomized Phase 2 with nivolumab + chemotherapy) | 1L HER2-negative metastatic GEA | antibody | Phase 2 |
| VIS-101 (tetravalent VEGF-A x ANG-2 peptibody; Visara) | Neovascular AMD, DME, RVO | protein/peptide | Phase 2 |
| Givastomig (Phase 1b cohorts) | 1L biliary tract cancer; 1L pancreatic ductal adenocarcinoma | antibody | Phase 1 |
| VIS-102 (HT006.2.2, modified rhNGF; in-licensed by Visara 2026-10-13) | Neurotrophic keratitis | protein/peptide | Phase 1 |
| Ragistomig (ABL503), PD-L1 x 4-1BB (ABL Bio leads) | Solid tumors | antibody | Phase 1 |
| Uliledlimab, CD73 antibody (partnered with TJ Bio) | NSCLC | antibody | Phase 1 |
Recent results and decisions
- Oct 25, 2026positive Updated Phase 1b study of givastomig with nivolumab and chemotherapy shows 79% objective response rate and 16.9 months median PFS at 8 mg/kg dose with nearly 18 months median follow-up.
Objective response rate of 79% (23/29), disease control rate of 97% (28/29), median duration of response of 15.2 months, median progression-free survival of 16.9 months, median follow-up of 17.8 months
Filing - Mar 9, 2026positive Phase 2a (n=38, China): mean BCVA gain >10 ETDRS letters, median CST reduction 100-150, about half of patients retreatment-free at 6 months, no dose-limiting toxicity.
Topline results show that VIS-101 produced rapid, robust and durable treatment responses in wet AMD, with potential best-in-class durability and a favorable safety profile.
Filing - Dec 10, 2025positive Phase 1 Q6W cohort: DCR 58.8% vs 64.3% on Q2W, ORR 11.8% vs 28.6%, with Grade 3+ LFT elevation in 5% vs 40% of patients.
Ragistomig demonstrated comparable anti-tumor efficacy for the Q6W dose schedule compared to the Q2W regimen (58.8% disease control rate (DCR) at Q6W compared to 64.3% at Q2W)
Filing
1 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 oncology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.